Granules India Limited (GRANULES) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹797.25 (-0.41% day change)
Key ratios
- P/E ratio
- 32.58
- P/B ratio
- 2.97
- ROE (%)
- 11.7
- ROCE (%)
- 15.8
- Debt/Equity
- 0.3
- Dividend yield (%)
- 0.24
- Market cap (₹ Cr)
- 19,755.62
Forensic checks
Piotroski F-Score: 6/9 · Altman Z-Score: 9 · Beneish M-Score: -2.57
InvestSights quality score
73/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Quarterly R&D spending: guided 40–45Rs Cr, delivered 57Rs Cr (Q3 FY25) — exceeded guidance
- Quarterly R&D spending: guided 35–40Rs Cr, delivered 57Rs Cr (Q3 FY25) — exceeded guidance
Latest earnings call (Q2 FY27)
AI summary: The most important signal is that Granules is attempting to convert several years of investment into a differentiated, operating-leverage-led growth phase, rather than relying primarily on its legacy high-volume portfolio. Controlled substances provide the strongest current proof point: Granules has moved from eighth in July 2025 to the third-largest US controlled-substance…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.